Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38&agr; MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation: Heart Failure

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.109.900282PMID 20466848PMCID PMC3075465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury.

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Preconditioning: the mitochondrial connection.

  2007cited by this paper
• Aging is associated with myocardial insulin resistance and mitochondrial dysfunction.

  2007cited by this paper
• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

  2006cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines

  2005cited by this paper
• The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.

  2004cited by this paper
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.

  2004cited by this paper
• Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium.

  2004cited by this paper
• Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB.

  2004cited by this paper
• Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1

  2003cited by this paper
• Acute effects of troglitazone and nitric oxide on glucose uptake in L929 fibroblast cells.

  2003cited by this paper
• Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling.

  2003cited by this paper
• Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.

  2002cited by this paper
• Block of the ryanodine receptor channel by neomycin is relieved at high holding potentials.

  2002cited by this paper
• The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.

  2002cited by this paper
• Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.

  2001cited by this paper
• Glucagon-like peptide-1.

  2001cited by this paper
• Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes

  2001cited by this paper
• Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

  2001cited by this paper
• Mechanisms whereby rapid RV pacing causes LV dysfunction: perfusion-contraction matching and NO.

  2001cited by this paper
• Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function.

  2000cited by this paper
• Expression of Adenylyl Cyclase Subtypes in Pancreatic β-Cells

  1999cited by this paper
• Expression of adenylyl cyclase subtypes in pancreatic beta-cells.

  1999cited by this paper
• Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

  1998cited by this paper
• Glucose transporter expression in L6 muscle cells: regulation through insulin- and stress-activated pathways.

  1997cited by this paper
• Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites.

  1997cited by this paper
• The adenylyl cyclases as integrators of transmembrane signal transduction.

  1997cited by this paper
• Nitric Oxide Stimulates Skeletal Muscle Glucose Transport Through a Calcium/Contraction– and Phosphatidylinositol-3-Kinase–Independent Pathway

  1997cited by this paper
• Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

  1996cited by this paper
• Determination of nitric oxide using fluorescence spectroscopy.

  1996cited by this paper
• Distribution of GLP-1 and PACAP receptors in human tissues.

  1996cited by this paper
• Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.

  1996cited by this paper
• Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against.

  1995cited by this paper
• Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

  1994cited by this paper
• Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function.

  1994cited by this paper
• Myocardial B-adrenergic receptor function during the development of pacing-induced heart failure

  1994cited by this paper
• Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure.

  1993cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells*

  year unknowncited by this paper

• GLP-1 and the cardiovascular system

  2026cites this paper
• Insight into novel therapeutic targets in heart failure: a comprehensive review

  2025cites this paper
• Advancing Heart Failure Care: Breakthroughs and Emerging Strategies

  2025cites this paper
• Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect

  2024cites this paper
• GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms

  2024cites this paper
• Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction

  2024cites this paper
• Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF

  2024cites this paper
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

  2023cites this paper
• Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?

  2022cites this paper
• The Coadministration of Levosimendan and Exenatide Offers a Significant Cardioprotective Effect to Isolated Rat Hearts against Ischemia/Reperfusion Injury

  2022cites this paper
• Electrocardiographic, hemodynamic, and biochemical evidence on the protective effects of exenatide against phosphine-induced cardiotoxicity in rat model

  2021cites this paper
• The effects of eight weeks high intensity interval training on the levels of endothelial nitric oxide synthase (eNOS) gene expression in left ventricle of type 2 diabetic rats

  2021cites this paper
• GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation

  2020cites this paper
• The GLP-1R Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.

  2020cites this paper
• Changes in Myocardial Metabolism Preceding Sudden Cardiac Death

  2020cites this paper
• Liraglutide alleviates cardiac fibrosis through inhibiting P4h&agr;-1 expression in STZ-induced diabetic cardiomyopathy

  2019cites this paper
• The Intestine Responds to Heart Failure by Enhanced Mitochondrial Fusion through Glucagon-like Peptide-1 Signaling.

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Cardioprotection conferred by rooibos (Aspalathus linearis): A mini review to highlight a potential mechanism of action

  2019cites this paper
• Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

  2019cites this paper
• A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats

  2019cites this paper
• Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.

  2018cites this paper
• Effect of glucose-lowering therapies on heart failure

  2018cites this paper
• Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes

  2018cites this paper
• Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries

  2018cites this paper
• Contemporary Advances in Myocardial Metabolic Imaging and Their Impact on Clinical Care: a Focus on Positron Emission Tomography (PET)

  2018cites this paper
• Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.

  2017cites this paper
• Cardiovascular consequences of metabolic syndrome.

  2017cites this paper
• Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

  2017influential citation
• HEMODYNAMIC AND CARDIAC EFFECTS OF OBESITY AND THE METABOLIC SYNDROME

  2017cites this paper
• Exenatide Regulates Substrate Preferences Through the p38γ MAPK Pathway After Ischaemia/Reperfusion Injury in a Rat Heart.

  2017influential citation
• Sodium Butyrate Protects ­Against High Fat Diet‐Induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice

  2017cites this paper
• Mitochondrial dysfunction and its impact on diabetic heart.

  2017cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cites this paper
• Incretin-based therapies for the failing heart

  2016cites this paper
• Mechanisms for the cardiovascular effects of glucagon‐like peptide‐1

  2016influential citation
• Geniposide Prevents Hypoxia/Reoxygenation-Induced Apoptosis in H9c2 Cells: Improvement of Mitochondrial Dysfunction and Activation of GLP-1R and the PI3K/AKT Signaling Pathway

  2016cites this paper
• Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

  2016cites this paper
• Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.

  2016cites this paper
• Cell Signaling : Proteins , Pathways and Mechanisms Exendin-4 induces myocardial protection through MKK 3 and Akt1 in infarcted hearts

  2016cites this paper
• Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

  2016cites this paper
• Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches.

  2016cites this paper
• Endothelial Restoration of Receptor Activity–Modifying Protein 2 Is Sufficient to Rescue Lethality, but Survivors Develop Dilated Cardiomyopathy

  2016influential citation
• Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in adult male albino rats

  2016cites this paper
• Novel Functions of Adrenomedullin, Receptor Activity-Modifying Protein 2, and Gpr182 in Cardiovascular Disease and Cancer

  2016cites this paper
• Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition

  2016cites this paper
• Evolving Challenges for Targeting Metabolic Abnormalities in Heart Failure.

  2016cites this paper
• Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.

  2016cites this paper
• Obesity alters global response to ischemia and GLP-1 agonism

  2016cites this paper
• SIRT1: role in cardiovascular biology.

  2015cites this paper
• Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.

  2015cites this paper
• Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

  2015cites this paper
• Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials

  2015cites this paper
• Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.

  2015cites this paper
• Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

  2015cites this paper
• Dehydrozingerone exerts beneficial metabolic effects in high-fat diet-induced obese mice viaAMPK activation in skeletal muscle

  2015cites this paper
• Incretin-Related Drug Therapy in Heart Failure

  2015cites this paper
• Fuel Metabolism Plasticity in Pathological Cardiac Hypertrophy and Failure

  2014cites this paper
• Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs

  2014cites this paper
• Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia

  2014cites this paper
• Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited

  2014cites this paper
• Cardiovascular and hemodynamic effects of glucagon-like peptide-1

  2014cites this paper
• GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment Study

  2014cites this paper
• Incretin-based therapies: can we achieve glycemic control and cardioprotection?

  2014influential citation
• GLP-1 (7–36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles

  2014cites this paper
• Newest additions to heart failure treatment

  2014cites this paper
• Cardiovascular actions of incretin-based therapies.

  2014cites this paper
• GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum-mitochondria coupling.

  2014cites this paper
• DPP-IV inhibitors: Beyond glycaemic control?

  2014cites this paper
• Incretin therapy and heart failure.

  2014cites this paper
• Liraglutide and Insulin are Associated with a Decreased Risk of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients

  2014cites this paper
• Post-Genomic Analysis of Fatty Acid and Glucose Metabolism in Cardiovascular Disease

  2014cites this paper
• Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus

  2014cites this paper
• The incretin system in type 2 diabetes mellitus: cardiovascular effects

  2013cites this paper
• Pathological Ventricular Remodeling: Therapies Part 2 of 2

  2013cites this paper
• Direct cardiovascular effects of glucagon like peptide-1

  2013cites this paper
• Pathological Ventricular Remodeling: Mechanisms Part 1 of 2

  2013cites this paper
• Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model.

  2013cites this paper
• Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus

  2013influential citation
• Roles of p38-MAPK in insulin resistant heart: evidence from bench to future bedside application.

  2013cites this paper
• Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

  2013cites this paper
• Incretins as a novel therapeutic strategy in patients with diabetes and heart failure

  2013cites this paper
• Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.

  2013cites this paper
• Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study

  2013cites this paper
• Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

  2012cites this paper
• Potential cardiovascular effects of incretin-based therapies

  2012cites this paper
• Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates

  2012cites this paper
• Circulation: Heart Failure Editors' Picks Most Important Papers in Pathophysiology and Genetics

  2012cites this paper
• Myocardial Insulin Signaling and Glucose Transport Are Up-regulated in Goto–Kakizaki Type 2 Diabetic Rats After Ileal Transposition

  2012cites this paper
• Glucagon-Like Peptide-1 and its Cardiovascular Effects

  2012cites this paper
• The effect of glucagon-like peptide 1 on cardiovascular risk

  2012cites this paper
• Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow

  2012cites this paper
• Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

  2012cites this paper
• Cardiovascular biology of the incretin system.

  2012cites this paper
• Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease

  2012cites this paper
• A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes

  2012cites this paper
• Congestive Heart Failure and Diabetes: Balancing Glycemic Control with Heart Failure Improvement

  2012cites this paper
• Targeting myocardial substrate metabolism in heart failure: potential for new therapies

  2012cites this paper
• Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

  2012cites this paper
• Emerging beneficial roles of sirtuins in heart failure

  2012cites this paper